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Abstract
Extra-abdominal desmoid tumours are slow-growing, histologically benign tumours of fibroblastic
origin with variable biologic behaviour. They are locally aggressive and invasive to surrounding
anatomic structures. Magnetic resonance imaging is the modality of choice for the diagnosis and the
evaluation of the tumours. Current management of desmoids involves a multidisciplinary approach.
Wide margin surgical resection remains the main treatment modality for local control of the
tumour. Amputation should not be the initial treatment, and function-preserving procedures
should be the primary treatment goal. Adjuvant radiation therapy is recommended both for
primary and recurrent lesions. Chemotherapy may be used for recurrent or unresectable disease.
Overall local recurrence rates vary and depend on patient's age, tumour location and margins at
resection.
Background
Extra-abdominal desmoid tumours or aggressive fibroma-
toses are rare, slow-growing, histologically benign
tumours of fibroblastic origin, with variable biological
behaviour [1-3]. Desmoid tumours account for about
0.03% of all neoplasms, and less than 3% of all soft tissue
tumours. The estimated incidence in the general popula-
tion is 2 to 4 per million population per year [4].
Despite their benign appearance, they are locally aggres-
sive and invasive to surrounding anatomic structures.
Because of these characteristics, desmoid tumours are
often classified as low-grade fibrosarcomas [1,2,5,6].
Although aetiology is unknown, a connective tissue
growth disorder has been supported [7-10]. Desmoid
tumours have been associated with hereditary syndromes
(Gardner's syndrome), pregnancy, especially second preg-
nancy, and endogenous/exogenous female sex hormones
in adults. However in children, these associations are dif-
ficult to establish [4,10,11].
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Based on X-chromosome inactivation pattern, desmoid
tumours appear to be monoclonal disorders, indicative of
a neoplastic rather than an inflammatory fibrous reactive
process [5,8,13]. Other studies [7,9] have reported an
abnormal expression of c-sis and platelet-derived growth
factor (PDGF), which can be mitogen for fibrocytes, and a
somatic APC gene mutation in patients with increased lev-
els of beta-catenin, which may explain the proliferative
advantage of these cells. Besides loss-of-function muta-
tions of APC, gain-of-function mutations of beta-catenin
have also been described [9,14]. In addition, the tumour-
suppressor gene Rb1 has shown decreased expression and
may also play a role in the pathophysiology of the disease
[10].
Location
Desmoid tumors are fibroproliferative disorders arising
within musculoaponeurotic tissue, observed in nearly
every part of the body. Numerous sites in the trunk and
extremities have been identified, and two forms of the dis-
ease are distinguished; an extra-abdominal and an intra-
abdominal form. Generally, desmoids usually occur in
three locations; the extremities (commonly around the
limb girdles or the proximal extremities); the abdominal
wall (commonly found in women, especially during and
after pregnancy); and the bowel wall and mesentery
(often associated with Gardner syndrome) [5,15].
In approximately 10% of the cases, multicentric disease
has been reported [16,17]. Multicentricity is defined as
the presence of disease in more than one location at the
time of diagnosis. Multicentric lesions tend to be in the
same limb or anatomic region, and it is possible that
many cases of distant or local recurrence of primary
lesions within the same region represent multicentric dis-
ease that were not clinically apparent at the initial diagno-
sis [4,16-19].
Natural history
The clinical behaviour and natural history of desmoid
tumours remain unpredictable. They are usually slow-
growing, locally aggressive and invasive to surrounding
tissues. Although both spontaneous regression and disap-
pearance have been reported, as has spontaneous regres-
sion after biopsy [2,5,20,21], most lesions will progress
refractory to multiple surgical procedures and adjuvant
therapy. They often recur after surgery, particularly after
marginal or intralesional excision. Distant haematoge-
nous or lymph nodes metastases have not been observed,
and multicentric disease and recurrence or reactivation at
sites other than the primary location have been reported
[16,17]. Extra-abdominal head and neck lesions are more
aggressive than extra-abdominal desmoids arising else-
where and are capable of massive destruction of adjacent
bone and erosion of the base of the scull, and occasionally
encroach on the trachea, some times with fatal outcome.
[2,19,22-24]. Loss of function may be observed with
extra-abdominal tumours involving the extremities, as
result of wide resection, local recurrence, and radiation
therapy [2,5].
Imaging
Although computed tomography shows the extent of the
tumour and its relationship to the neurovascular struc-
tures (Figure 1), magnetic resonance imaging (MRI) is the
modality of choice for the diagnosis and the evaluation of
the tumours' extent and the progression of the disease
after treatment (Fig 2). MRI features vary. Heterogeneous
changes are common, depending on the distribution of
collagen and the cellularity of the lesions [25,26]. The
lesions may be hypo- or hyper-intense relative to sur-
rounding muscle or adipose tissue (Fig 2B,C), on both T1-
and T2-weighted sequences, with both sharply and poorly
defined margins [26,27].
MRI with gadolinium injection may also be helpful in dif-
ferentiating tumour progression from post-surgical fibro-
sis [26]. Multicentric and recurrent lesions tend to occur
within the same limb or anatomic region, which outlines
the role of scanning the entire extremity once the diagno-
sis is made [17].
Pathology
On gross examination, the tumours are always confined
to the musculature and the overlying aponeurosis or fas-
cia (Figure 3). Their size varies from 5 to 20 cm. The
tumours are firm, cut with a gritty sensation, and on cross
section reveal a glistening white, coarsely trabeculated sur-
face resembling scar tissue [24].
Computed tomography scan of the left thigh shows a large  soft tissue mass involving the vastus lateralis muscle Figure 1
Computed tomography scan of the left thigh shows a large 
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Microscopically, desmoid tumours are poorly circum-
scribed, infiltrating the surrounding tissue. The prolifera-
tion consists of elongated, slender, spindle-shaped cells of
uniform appearance. The tumour cells are surrounded
and separated from one another by abundant collagen,
with little to no cell-to-cell contact (Figure 4A,B). The cells
lack atypia, but cellularity may vary within the same
lesion. Nuclei are small, pale-staining, and sharply
defined. One to three small nucleoli are usual [24,28].
Ultrastructurally, desmoid tumours consist of a uniform
population of elongated fibroblast-like cells, often termi-
nating in long, slender processes [24,29]. Most nuclei are
rounded or oval, but some cells show prominent nuclear
indentations or clefts. There is a prominent rough endo-
plasmic reticulum, partly dilated, containing granular or
fibrillary material within the dilated spaces. The cyto-
plasm has a small number of mitochondria, a prominent
Golgi apparatus, free ribosomes, and occasional pinocy-
totic vesicles and microtubules. Some cells contain intrac-
ytoplasmic bundles of actin-type microfilaments, and
incomplete or clumped basal lamina along the cell bor-
ders, all features characteristic of myofibroblasts. The
stroma contains considerable amounts of collagen and
ground substance [24,29].
Differential diagnosis
Differential diagnosis includes fibrosarcoma, reactive
fibroblastic proliferations, desmoplastic fibroma,
myxoma, and nodular fasciitis [24,30].
Desmoids most closely resemble fibrosarcomas. An inad-
equate biopsy specimen may lead to misdiagnosis, as
some examples of fibrosarcomas have areas indistinguish-
able from desmoid tumours and vice versa [24].
Desmoids may also be difficult to be distinguished from
reactive fibroblastic proliferations following injuries such
as trauma, minor muscle tears, or intramuscular injec-
tions. Cytologically, these reactive proliferations are com-
posed of cells indistinguishable from those found in
desmoid tumours, and the low-magnification appearance
is more useful for differential diagnosis of these two enti-
ties. Desmoplastic fibroma of bone may also be indistin-
guishable from desmoid tumours, especially when
presents as a soft tissue mass after breaking through the
thinned or expanded cortex of the involved bone. Confu-
sion with myxoma or nodular fasciitis is possible, partic-
ularly if only a small amount of tissue or FNA is available
for examination [24].
Fibrosarcomatous transformation of desmoid tumours is
rare, and it may be erroneously suggested by occasional
foci of increased cellularity and by exceptionally well-dif-
Photograph of the gross specimen excised shows a compact  fibrous and lobulated soft tissue tumour Figure 3
Photograph of the gross specimen excised shows a compact 
fibrous and lobulated soft tissue tumour.
Magnetic tomography imaging (A) axial T1-weighted, (B) T2-weigthed, and (C) coronal T1-weighted views show a well-cir- cumscribed heterogeneous soft tissue mass within the left vastus lateralis muscle Figure 2
Magnetic tomography imaging (A) axial T1-weighted, (B) T2-weigthed, and (C) coronal T1-weighted views show a well-cir-
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ferentiated fibromatosis-like areas in some fibrosarcomas
[24].
Management
Current management of desmoid tumours involves a
multidisciplinary approach. Radiation therapy or brachy-
therapy have been used in the adjuvant setting. Antiestro-
gens, goserelin, progesterone, non-steroidal anti-
inflammatory drugs (NSAIDs), interferon (IFN-alpha),
cytotoxic chemotherapeutic agents, and radiation therapy
have all been employed in the management of desmoids
[1,2,4,5,31-41].
Surgical treatment
Wide margin surgical resection remains the main treat-
ment option for local control of the tumour in all age
groups [3,18,19,21,22,24,39,42,43]. Although often diffi-
cult to achieve because of the tumour's extent and inva-
siveness, wide margin surgical resection offers the best
chance of avoiding local recurrence [3,19,21,24,42,44].
Desmoids frequently recur after surgery, and the benefits
of radical surgery and various adjuvants must be weighed
against the potential morbidity of the tumour, especially
in the skeletally immature patients. The rate of surgical
complications, such as joint contractures and poor func-
tion is also high [21].
Because of the infiltrative nature of these tumours, local
recurrence rates after wide local excision may be high.
Although several authors have reported a significantly
increased risk of local recurrence in patients with positive
or close resection margins, and intralesional or marginal
excision, others have found no differences in local recur-
rence rates between patients with positive or negative
margins [5,6,21,22,42-46]. Thus, the precise association
of the surgical resection margins with local recurrence risk
is difficult to evaluate [4,21,22,45,47,48]. Re-operation
for the treatment of recurrent disease is advocated by most
authors, resulting in a cure rate similar to that of the pri-
mary surgical resection [2,4,5,22]. Amputation should
not be a primary treatment. It is considered inevitable and
should be reserved for cases in which either recurrent dis-
ease or the effects of surgical treatment or irradiation have
resulted in a significant loss of function and/or chronic
symptoms [5,49].
Radiation therapy
External-beam radiation therapy has been shown to
improve local control of desmoid tumours, both in the
adjuvant and primary settings [5,6,21,46-48]. It has been
used as adjuvant mainly in adults for the treatment of
unresectable or inaccessible disease, for gross residual
tumour with positive or equivocal surgical margins, and
to avoid mutilating surgery [6,19,21,22,42,46-48,50,51].
Radiation doses of 50 to 60 Gy are currently suggested as
curative [2,5,6,22,42,44,46,47]. Lower doses are associ-
ated with higher rates of tumour progression and local
recurrence. Higher doses have resulted in complications,
including fibrosis, oedema, skin ulceration, neurological
deficits including paresthesias and paresis, pathologic
fractures, cellulitis, and secondary malignant transforma-
tion, which may also lead to a second stage amputation
[42,47-49,52,53].
Photomicrographs in (A) low-power and (B) high-power show elongated, slender, spindle-shaped cells of uniform appearance  without atypia Figure 4
Photomicrographs in (A) low-power and (B) high-power show elongated, slender, spindle-shaped cells of uniform appearance 
without atypia. The cells are surrounded and separated from one another by abundant collagen, with little to no cell-to-cell 
contact.World Journal of Surgical Oncology 2006, 4:21 http://www.wjso.com/content/4/1/21
Page 5 of 8
(page number not for citation purposes)
When used as adjuvant, irradiation is reported to achieve
disease control in 77 to 90% of patients [6,12,42,54]. In
cases of positive surgical margins, adjuvant radiation ther-
apy is recommended when the potential morbidity of a
second operation is high [5,6,12,42,44,45,50,54,55]. Int-
ralesional excision in addition to radiotherapy is ineffec-
tive, with high local recurrence rates and life threatening
complications for the patient. Under these circumstances
doses above 50 Gy are recommended [2,12].
In children, desmoid tumours are highly aggressive, and
data are not in favour of the use of irradiation because of
the previously mentioned complications and the risks of
contractures development and growth disturbance
[18,19,40,52,53]. Most children are treated with radiation
therapy using guidelines outlined for adults. External
beam radiation therapy in children should be performed
as a last resort, in patients reaching skeletal maturity, in
cases with potential mortality or significant morbidity,
and in tumours showing active growth adjacent to vital
structures or progressive disease after multiple attempts at
control with surgery and chemotherapy. Otherwise, when
safe surgical margins can be achieved, no additional ther-
apy is recommended, despite a risk of recurrence ranging
from 5% to 50% [4,12,18,19,54].
Management of recurrent or inoperative lesions
The role of radiation therapy is discussed above. Because
of its low toxicity endocrine therapy is frequently the first
line of treatment for recurrent desmoid tumours, which
are not candidates for surgical or radiation approaches.
The use of hormonal therapy for the treatment of these
tumours is based on the association of oestrogen levels
with the growth of desmoid tumours, and on estrogen
receptor expression in desmoids [56,57]. A higher inci-
dence of these tumours, especially in the abdominal wall,
is reported during or soon after pregnancy, or during treat-
ment with oral contraceptives [37,58,59]. There have also
been reports of spontaneous regression of desmoids after
menopause and oophorectomy [4,45]. Endocrine treat-
ment with agents such as tamoxifene have resulted in
response rates of up to 50% in older series [38]. Other
hormonal agents employed in the treatment of desmoids
include medroxyprogesterone acetate, megace, toremifen,
and gonadotropin releasing hormone analog goserelin in
tamoxifen failures
Non-steroid anti-inflammatory drugs such as indometh-
acin or sulindac as single agents or in combination with
antioestrogens [60,61] have also been used in the treat-
ment of desmoid tumours, with variable response rates
being reported mostly based on small series and case
reports [5,37].
Use of IFN-alpha in desmoids has also been reported in
inoperable cases [62], and in combination with tretinoin
in order to delay of local recurrence. Without clear evi-
dence for long term benefits however, IFN-alpha therapy
because of its relative lack of toxicity, it might be appropri-
ate to consider in cases where mutilating surgery or more
toxic medical treatment would be the other treatment
alternative [1,32,34,35,45,63-65].
Chemotherapy
Cytotoxic chemotherapeutic agents have been used in
inoperable or unresectable tumours, progressive or resid-
ual disease, and in rare cases as neoadjuvant to facilitate
wide surgical resection. Although their histological
appearance might suggest otherwise, desmoid tumours do
respond to chemotherapy with symptomatic relief and
occasionally durable disease regression. In children, com-
bination chemotherapy may be indicated for inaccessible
disease or in cases in which local control could not be
achieved [5,18,32,37,52,53,59,60,66,67].
Low dose combination of vinblastine and methotrexate,
vincristine, actinomycin D, cyclophosphamide, and dox-
orubicin/dacarbazine [2,66] have been used for sympto-
matic relief, tumour growth retardation in children in
order to delay radiation therapy until skeletal maturity
[5,66,68-70]. In one trial of 30 patients, weekly vinblastin
and methotrexate resulted in a partial response rate of
40% and disease stability in 60% of patients. After a
median follow-up of 75 months the 10 year actuarial pro-
gression free interval was 67% [71]. In another study of 7
patients treated with combinations of cyclophosphamide
and doxorubicin, mitomycin, and etoposide objective
regression was observed in 3 patients with duration of
benefit ranging from 3 months to 15 years [49]. Finally in
familiar adenomatous polyposis patients with desmoid
tumours, a doxorubicin/dacarbazine combination fol-
lowed by treatment with COX-2 inhibitor meloxicam
resulted in objective responses in all 7 patients treated
with a median progression free survival of 74 months.
[72]
Prognosis
Although neither haematogenous nor lymphatic metas-
tases have been observed, most lesions will progress
refractory to treatment. Spontaneous regression and dis-
appearance, regression after biopsy, multicentric disease,
and recurrence or reactivation at sites other than the pri-
mary location have all been reported [2,5,20,21]. Mortal-
ity is rare in extra-abdominal desmoid tumours, but has
been reported in head and neck lesions. Loss of function
is often observed with involvement of the extremities
[19,22,23].World Journal of Surgical Oncology 2006, 4:21 http://www.wjso.com/content/4/1/21
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Overall local recurrence rates range from 19% to 75%
[4,18,21,22,24,42,51]. Most recurrences are usually
observed within 3 years, and nearly all by 6 years [2,18].
Age may affect recurrence rates, and although unclear,
local recurrence may be more likely in younger patients
with extra-abdominal lesions [2,4]. The region of involve-
ment also affects local recurrence, which is reported
higher in extra-abdominal lesions of the foot and calf.
Extremity tumours, because of their locally aggressive
behaviour have the higher propensity for local recurrent
growth [5]. Local recurrence rates for intra-abdominal
tumours are higher than those reported for extra-abdomi-
nal tumours, ranging from 57% to 86% after complete
resection, with a higher complications rate and even death
[5,15].
Conclusion
Desmoid tumours are challenging with unpredictable nat-
ural history. Current management involves a multidisci-
plinary approach. Wide margin surgical resection remains
the main treatment modality for local control of the
tumour in all age groups. Amputation should not be a pri-
mary treatment and should be reserved for refractory cases
or for those in whom the disease or its treatment have
resulted in a non-functional or chronically painful
extremity. Function and structure-preserving procedures
should be the primary treatment goal.
Non-surgical treatment involving irradiation, brachyther-
apy, endocrine therapy and cytotoxic chemotherapy has
resulted in diverse and unpredictable outcome. External-
beam radiation therapy can be used as adjuvant mainly in
adults, while in the skeletally immature patients should
be used as a last resort in selected cases. Combination
chemotherapy may be indicated for unresectable disease.
Overall local recurrence rates vary, depending on patient's
age, tumour location and margins at resection. Disease
progression may occur many years after treatment, and
patients should be constantly surveyed. Future research
efforts forwards development of targeted therapeutics
may improve patients' outcome.
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